Clin Oncol | Volume 6, Issue 1 | Case Series | Open Access

BCL2 Antagonist Venetoclax Combined with Non-Aggressive Chemotherapy in Treating Fatal TCF3-HLF Positive Acute  Lymphoblastic Leukemia

Wang P, He Y, Wang J, Ye Q, Zhang H* and Zhang W*

Department of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, China

*Correspondance to: Weina Zhang 

Fulltext PDF


TCF3-HLF-fusion positive Acute Lymphoblastic Leukemia (ALL) is very rare and nearly incurable according to current standard chemotherapy even with hematopoietic stem cell transplantation. Optimized treatment strategies are urgently needed. In this report we present two cases with TCF3-HLF fusion with different therapeutic regimens and review ever reported cases in  literature. We proposed that combination of BCL2 antagonist venetoclax with non-aggressive chemotherapy should be considered for this fatal subtype ALL in the future.


TCF3-HLF; Acute lymphoblastic leukemia; BCL2 antagonist venetoclax; Nonaggressive chemotherapy


Wang P, He Y, Wang J, Ye Q, Zhang H, Zhang W. BCL2 Antagonist Venetoclax Combined with Non-Aggressive Chemotherapy in Treating Fatal TCF3-HLF Positive Acute Lymphoblastic Leukemia. Clin Oncol. 2021;6:1830..

Subscribe to Our Newsletter